Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Apr 23:15:1414392.
doi: 10.3389/fendo.2024.1414392. eCollection 2024.

Editorial: Resistance to endocrine therapies in cancer, volume II

Anindita Chakrabarty  1 , Stephen Hiscox  2 , Prathibha Ranganathan  3
Affiliations
Editorial

Editorial: Resistance to endocrine therapies in cancer, volume II

Anindita Chakrabarty et al. Front Endocrinol (Lausanne). .
No abstract available

Keywords: androgen; breast cancer; endocrine therapy; estrogen; prostate cancer; resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Comment on

  • Editorial on the Research Topic Resistance to endocrine therapies in cancer, volume II

References

    1. Kwok J, O’Shea M, Hume DA, Lengeling A. Jmjd6, a jmjC dioxygenase with many interaction partners and pleiotropic functions. Front Genet. (2017) 8:32. doi: 10.3389/fgene.2017.00032 - DOI - PMC - PubMed
    1. Poulard C, Corbo L, Le Romancer M. Protein arginine methylation/demethylation and cancer. Oncotarget. (2016) 7:67532–50. doi: 10.18632/oncotarget.v7i41 - DOI - PMC - PubMed
    1. Xiao RQ, Ran T, Huang QX, Liu W. A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo . Proc Natl Acad Sci USA. (2022) 119:e2200753119. doi: 10.1073/pnas.2200753119 - DOI - PMC - PubMed
    1. Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, et al. . JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res. (2012) 14:R85. doi: 10.1186/bcr3200 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances